Stefan Norin

766 total citations
28 papers, 393 citations indexed

About

Stefan Norin is a scholar working on Genetics, Oncology and Hematology. According to data from OpenAlex, Stefan Norin has authored 28 papers receiving a total of 393 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 12 papers in Oncology and 11 papers in Hematology. Recurrent topics in Stefan Norin's work include Chronic Lymphocytic Leukemia Research (14 papers), Multiple Myeloma Research and Treatments (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Stefan Norin is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Multiple Myeloma Research and Treatments (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Stefan Norin collaborates with scholars based in Sweden, United States and Spain. Stefan Norin's co-authors include Anders Österborg, Jeanette Lundin, Eva Kimby, Karin Karlsson, Lotta Hansson, Claes Karlsson, Birgitta Lauri, Hans Hägglund, Mattias Mattsson and Anna Sandstedt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Haematologica.

In The Last Decade

Stefan Norin

26 papers receiving 386 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stefan Norin Sweden	9	216	185	131	127	112	28	393
Arnau Montraveta Spain	12	236 1.1×	182 1.0×	103 0.8×	281 2.2×	96 0.9×	17	492
Gillian Turner United Kingdom	8	294 1.4×	266 1.4×	234 1.8×	107 0.8×	65 0.6×	13	531
Stéphanie Guidez France	10	134 0.6×	172 0.9×	155 1.2×	126 1.0×	57 0.5×	45	387
Brian Munneke United States	7	161 0.7×	219 1.2×	170 1.3×	61 0.5×	54 0.5×	13	337
Marinus van Oers Netherlands	9	183 0.8×	137 0.7×	100 0.8×	104 0.8×	88 0.8×	17	325
Carsten Schwänen Germany	6	329 1.5×	325 1.8×	187 1.4×	103 0.8×	106 0.9×	8	497
Tamia Nguyen Australia	7	328 1.5×	204 1.1×	77 0.6×	159 1.3×	109 1.0×	15	465
Ewa Wąsik‐Szczepanek Poland	10	279 1.3×	158 0.9×	75 0.6×	79 0.6×	196 1.8×	44	396
Gavin Babbage United Kingdom	6	242 1.1×	254 1.4×	142 1.1×	109 0.9×	154 1.4×	9	433
Bertrand Anz United States	7	472 2.2×	391 2.1×	103 0.8×	63 0.5×	168 1.5×	20	543

Countries citing papers authored by Stefan Norin

Since Specialization

Citations

This map shows the geographic impact of Stefan Norin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Norin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Norin more than expected).

Fields of papers citing papers by Stefan Norin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Norin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Norin. The network helps show where Stefan Norin may publish in the future.

Co-authorship network of co-authors of Stefan Norin

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Norin. A scholar is included among the top collaborators of Stefan Norin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Norin. Stefan Norin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schjesvold, Fredrik, Heinz Ludwig, Sossana Delimpasi, et al.. (2024). Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica. 109(7). 2331–2336.

Mateos, María‐Victoria, Jelena Bila, Fredrik Schjesvold, et al.. (2023). P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI. HemaSphere. 7(S2). 29–30. 1 indexed citations

Schjesvold, Fredrik, Heinz Ludwig, Sosana Delimpasi, et al.. (2023). P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY. HemaSphere. 7(S2). 32–32. 1 indexed citations

Pour, Luděk, Jelena Bila, Fredrik Schjesvold, et al.. (2023). Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study. Haematologica. 109(3). 895–905. 6 indexed citations

Ocio, Enrique M., Yvonne A. Efebera, Roman Hájek, et al.. (2020). ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety. Blood. 136(Supplement 1). 9–10. 15 indexed citations

Ocio, Enrique M., Yvonne A. Efebera, Miquel Granell, et al.. (2019). ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI). Blood. 134(Supplement_1). 3124–3124. 12 indexed citations

Johansson, Hemming, Jenny Klintman, Eva Kimby, et al.. (2018). First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. Haematologica. 104(4). 797–804. 28 indexed citations

Schilder, Russell J., et al.. (2018). A phase 1/2 study with birinapant in combination with pembrolizumab.. Journal of Clinical Oncology. 36(15_suppl). TPS3131–TPS3131. 3 indexed citations

Johansson, Hemming, Jenny Klintman, Eva Kimby, et al.. (2017). Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013. Blood. 130. 1744–1744. 1 indexed citations

10.

Andersson, Per‐Ola, Karin Karlsson, Claes Karlsson, et al.. (2017). Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program. Blood. 130. 5353. 2 indexed citations

11.

Andersson, Per, Karin Karlsson, Claes Karlsson, et al.. (2016). Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 101(12). 1573–1580. 76 indexed citations

12.

Norin, Stefan, et al.. (2015). Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study. Experimental Hematology. 44(1). 38–49.e1. 7 indexed citations

13.

Norin, Stefan, et al.. (2014). Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study. Leukemia Research. 39(1). 33–37. 4 indexed citations

14.

Hansson, Lotta, et al.. (2013). Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region. Leukemia & lymphoma. 55(8). 1774–1780. 8 indexed citations

15.

Daneshmanesh, Amir Hossein, Anna Porwit, Mohammad Hojjat‐Farsangi, et al.. (2012). Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leukemia & lymphoma. 54(4). 843–850. 63 indexed citations

16.

Gunnarsson, Rebeqa, Larry Mansouri, Anders Isaksson, et al.. (2011). Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica. 96(8). 1161–1169. 73 indexed citations

17.

Yakimchuk, Konstantin, Stefan Norin, Eva Kimby, et al.. (2011). Up-regulated estrogen receptor β2 in chronic lymphocytic leukemia. Leukemia & lymphoma. 53(1). 139–144. 24 indexed citations

18.

Gunnarsson, Rebeqa, Anders Isaksson, Mahmoud Mansouri, et al.. (2009). Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: A high-resolution genomic screening in newly diagnosed patients. Lund University Publications (Lund University). 94. 354–354. 1 indexed citations

19.

Norin, Stefan, Eva Kimby, & Jeanette Lundin. (2009). Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia. Medical Oncology. 27(3). 820–825. 10 indexed citations

20.

Norin, Stefan, Eva Kimby, Bo‐Göran Ericzon, et al.. (2004). Posttransplant Lymphoma A Single-Center Experience of 500 Liver Transplantations. Medical Oncology. 21(3). 273–284. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact